<DOC>
	<DOCNO>NCT01229254</DOCNO>
	<brief_summary>The primary purpose study optimize drug exposure target population .</brief_summary>
	<brief_title>Evaluate Pharmacokinetics Safety MK-4448 Participants With Nonvalvular Atrial Fibrillation ( Study MK-4448-006 )</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Atrial Flutter</mesh_term>
	<mesh_term>Amiodarone</mesh_term>
	<criteria>In opinion investigator , participant require long term anticoagulation stroke prevention AF . Men woman ≥18 year age . Participant current NVAF atrial flutter ECG Holter documentation within past 12 month . Participant INR ≤ 2.2 allocation ( Visit 2 ) . A participant reproductive potential agrees remain abstinent use ( partner use ) 2 acceptable method birth control duration study . Acceptable method birth control : intrauterine device ( IUD ) , diaphragm spermicide , condom , vasectomy , hormonal contraception . Participant understand study procedure risk involve study , voluntarily agree participate give write informed consent . General Participant currently participate another drug study receive investigational drug within 30 day prior enrollment . Participant woman pregnant , lactate childbearing potential refuse use medically acceptable form contraception throughout study . Participant body weight less 40 kg ( 88 lb ) great 200 kg ( 440 lb ) . Participant routinely consume 2 alcoholic drink per day ( average &gt; 14 alcoholic drink per week ) great 5 drink within 2 hour occasion . Prohibited Medical Conditions Participant condition situation , opinion investigator , might pose risk participant interfere participation study . Conditions associate increase risk bleed Active bleeding . Conditions AF require chronic anticoagulation . Severe aortic mitral valvular disease require surgical intervention . Previous known history coagulopathy ( e.g . : Factor V Leiden , Protein C Deficiency , Protein S Deficiency , Antiphospholipid Syndrome , etc. ) . Active infective endocarditis . Participant history familial long QT interval ( QT interval portion electrocardiogram ( ECG ) onset Q wave end T wave , represent total time ventricular depolarization repolarization ) syndrome prolong Bazettcorrected QT interval ( QTcB ) ( male &gt; 470 msec ; female &gt; 480 msec ) baseline measure 12lead ECG . Participant serious pulmonary , hepatic , metabolic , gastrointestinal , central nervous system ( CNS ) psychiatric disease , endstage disease state , disease could interfere conduct validity study compromise participant safety . Participant history malignancy ≤ 5 year prior sign inform consent , except adequately treat basal cell squamous cell skin cancer situ cervical cancer ( melanoma , leukemia , lymphoma myeloproliferative disorder duration exclude ) . Participant history mental instability , drug/alcohol abuse within past 5 year , major psychiatric illness adequately control stable pharmacotherapy . Participant reversible cause atrial fibrillation ( i.e . : cardiac surgery , pulmonary embolism , untreated hyperthyroidism ) . Participant undergo pulmonary vein isolation surgery treatment AF . Participant severe , disable stroke within previous 6 month , stroke within previous 14 day , thromboembolism within previous 30 day transient ischemic attack ( TIA ) within 3 day prior Visit 1 . Participant require renal replacement therapy ( hemo peritoneal dialysis ) . Participant list define laboratory abnormality . Prohibited Medications Antiplatelet agent aspirin within 10 day prior Visit 1 ( exclude maintenance dose clopidogrel , prasugrel ticlopidine ) fibrinolytic agent within 30 day prior Visit 1 . Aspirin great 162 mg/day . Daily nonsteroidal antiinflammatory drug ( NSAID ) use . Dronedarone , verapamil ketoconazole . Vitamin K antagonist ( VKA ) anticoagulant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Betrixaban</keyword>
	<keyword>MK-4448</keyword>
	<keyword>nonvalvular atrial fibrillation</keyword>
</DOC>